PFE News 30.71 04/25/2014 05:59:26 Pfizer Inc (PFE)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pfizer Inc (PFE) 30.71 $PFE

Drugmakers' Q1 was anemic
at Investor's Business Daily - Thu Apr 24, 5:36PM CDT
Citing R&D and marketing costs, AstraZeneca (AZN) missed EPS estimates with a 17% drop to $1.17. Flat sales of $6.4 bil did beat views. Eli Lilly (LLY) met EPS views of 70 cents, but sales fell 16% to $4.7 bil. Novartis (NVS) EPS slid 3% to $1.28,...

Actavis got a Pfizer
at Investor's Business Daily - Thu Apr 24, 5:36PM CDT
Actavis (ACT) got a Pfizer (PFE) license to start selling a generic form of painkiller Celebrex by Dec. or before, pending FDA OK. Teva (TEVA) and Pfizer reached a similar deal last week. Actavis shares fell 0.4%.

3 Drugs Johnson & Johnson’s Investors Better Know About
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Johnson & Johnson's  sales grew 3.5% during the past year, but only because of big sales growth from a handful of its recently launched drugs. Among these fast-growing new drugs are Johnson's next-generation treatment for diabetes, a new...

Most active New York Stock Exchange-traded stocks
AP - Thu Apr 24, 5:05PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:

Final Glance: Pharmaceuticals companies
AP - Thu Apr 24, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Pfizer to help investors with dividend, buybacks
By The Associated Press - AP - Thu Apr 24, 4:08PM CDT
SHORT HILLS, N.J. (AP) — Pfizer Inc. CEO Ian Read says the drugmaker will keep working to boost shareholder value, with continuing stock buybacks and healthy dividends.

Midday Glance: Pharmaceuticals companies
AP - Thu Apr 24, 12:27PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

AstraZeneca (AZN) Stock Higher Over Pfizer (PFE) Takeover Talk As Earnings Drop
at The Street - Thu Apr 24, 11:31AM CDT
Shares of AstraZeneca (AZN) are up 3.10% to $69.88 as Pfizer (PFE) takeover talk grows even though the biopharmaceutical company reported lower first quarter earnings.

Watch for Shares of Pfizer (PFE) to Approach Support at $30.53
Comtex SmarTrend(R) - Thu Apr 24, 10:43AM CDT
Shares of Pfizer (NYSE FE) have bearishly opened below the pivot of $30.95 today and have reached the first support level of $30.73. Should the shares continue to fall, the support pivots of $30.53 and $30.11 will be of interest.

Global Hypertension Drugs Market 2014-2018 with Actelion, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Sanofi Dominating
M2 - Thu Apr 24, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brq49m/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies. The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/brq49m/global

Dow Today: Pfizer (PFE) Lower
at The Street - Thu Apr 24, 10:00AM CDT
Holding back the Dow today is Pfizer (NYSE: PFE ), which is lagging the broader Dow index with a 51-cent decline (-1.6%) bringing the stock to $30.41.

Pfizer Hosts Annual Meeting of ShareholdersDeclares 26-Cent Second-Quarter 2014 Dividend
Business Wire - Thu Apr 24, 9:50AM CDT
The board of directors of Pfizer Inc. today declared a 26-cent second-quarter 2014 dividend on the company's common stock, payable June 3, 2014, to shareholders of record at the close of business on May 9, 2014. The second-quarter 2014 cash dividend will be the 302nd consecutive quarterly dividend paid by Pfizer.

Early Glance: Pharmaceuticals companies
AP - Thu Apr 24, 9:33AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

Trade-Ideas: Pfizer (PFE) Is Today's "Roof Leaker" Stock
at The Street - Thu Apr 24, 9:12AM CDT
Trade-Ideas LLC identified Pfizer (PFE) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate

Is This Struggling Drugmaker Worth $100 Billion?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 24, 8:30AM CDT
The pharmaceutical world got a shock this week from   reports that  Pfizer    had engaged in informal talks with Big Pharma rival  AstraZeneca    about a possible $100 billion acquisition. AstraZeneca reportedly  expressed no interest in the...

Actavis Announces Celebrex® Patent Challenge Settlement
PR Newswire - Thu Apr 24, 8:20AM CDT
Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Pfizer, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Celebrex® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. Celebrex® is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.

Merck, P&G and Other Dividend Stocks You Wish You'd Bought in 2013
at The Street - Thu Apr 24, 5:00AM CDT
I've covered these dividend winners before, but you're not too late to get on board.

European Stocks Rebound Amid M&A, Earnings Headlines
at The Street - Thu Apr 24, 4:56AM CDT
European stocks rebound on Thursday amid mergers and acquisitions excitement.

Will These 3 Dividend Stocks Impress Investors This Earnings Season?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Earnings season already has produced its fair share of surprises, but big pharma's hardly even broken out of the gate so far. However, a trio of major drugmakers are set to release their quarterly results in the next two weeks, and all eyes in the...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 95

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 188

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 164

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 53

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 149

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading

Top 5 Most Recently Viewed Articles

Essential Guidance to Avoid Contractor Fraud After Disasters

Updated Category News Views 249

Essential Guidance for Consumers: Preventing Contractor Fraud In times of devastating natural disasters, such as those caused by wildfires, consumers often find themselves in vulnerable positions. High winds and dry conditions can lead to situations where homes, businesses, and even schools suffer severe damage. It’s in these challenging times that the threat of...

Continue Reading
Stefan Vinberg: A Visionary Leader in Sustainable Real Estate

Updated Category News Views 60

Stefan Vinberg Achieves Dual Recognition at Prestigious Awards Stefan Vinberg, the respected CEO of Insig AB, has recently received outstanding recognition by winning two significant accolades at the Business Worldwide Magazine CEO Awards. These notable honors are the 'Sustainable Real Estate Leadership Award' and 'Growth Strategy CEO of the Year - Sweden'. This...

Continue Reading
SIME Diagnostics Unveils Breakthrough in Neonatal Lung Testing

Updated Category News Views 344

Introduction to AI in Neonatal Medicine SIME Diagnostics is transforming neonatal care with its innovative approach to evaluating lung maturity in preterm infants. This UK-based medical technology company has recently completed a significant clinical study aimed at addressing respiratory challenges faced by late-preterm newborns. The findings promise not only to enhance...

Continue Reading
Baxter Intl's Q4 Results: Key Takeaways and Insights

Updated Category News Views 164

Understanding Baxter Intl's Q4 Earnings The recent earnings report from Baxter Intl (NYSE: BAX) provides crucial insights for investors and analysts alike. In the fourth quarter, the company revealed some significant insights into its financial health and market performance, prompting a closer examination of what this means for shareholders. Earnings Performance Overview...

Continue Reading
Morgan Stanley Sheds Light on UK Investment Trends

Updated Category News Views 99

Insights on UK Investment Intentions From Morgan Stanley Recently, UK assets have captured significant attention, prompting Morgan Stanley (NYSE: MS) to conduct a survey aimed at understanding investors' views, intentions, and positions regarding these assets. This survey highlights the current sentiment surrounding investments in the UK amid uncertain market conditions....

Continue Reading